An Analysis of IL-10/IL-10R Genetic Factors Related to Risk of Colon Cancer and Inflammatory Bowel Disease in a Han Chinese Population

被引:8
作者
Cai, Jun [1 ,2 ,3 ]
Zhang, Zhongtao [1 ,2 ]
机构
[1] Capital Med Univ, Dept Gen Surg, Beijing Friendship Hosp, Beijing Key Lab Canc Invas & Metastasis Res, Beijing, Peoples R China
[2] Natl Clin Res Ctr Digest Dis, Beijing, Peoples R China
[3] Peking Univ Int Hosp, Dept Hepatobiliary Surg, Beijing, Peoples R China
关键词
interleukin-10; interleukin-10R; polymorphism; colon cancer; inflammatory bowel diseases; COLORECTAL-CANCER; PROMOTER POLYMORPHISMS; ULCERATIVE-COLITIS; INTERLEUKIN-10; SUSCEPTIBILITY; ASSOCIATION; IL-10; VARIANTS;
D O I
10.7754/Clin.Lab.2015.151120
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Background: Patients with chronic inflammatory bowel disease (IBD) are at high risk of developing colon cancer and represent a valuable patient cohort for studying the correlation between chronic inflammation and cancer formation. Cytokines play key roles in the regulation of systemic inflammation, local tissue damage, and immunomodulation involved in tumor development and progression. Therefore, functional polymorphisms in genes that encode cytokines and cytokine receptors represent potential candidate genes associated with carcinogenesis. The present study aimed to ascertain if any of the candidate single nucleotide polymorphisms (SNPs) in inflammation related genes IL-10/IL-10R are associated with colon cancer or IBD in Han Chinese population. Methods: A case-control study in a Chinese Han cohort was conducted and included 375 patients with colon cancer, 278 patients with IBD, and 382 age and gender matched healthy controls. Genotyping of four candidate SNPs (IL-10 rs1800896, rs1800872, rs3024505, and IL-10R rs9610) was performed and analysis was done using the MassARRAY system based on the MALDI-TOF MS platform. Results: The C allele at rs1800872 may be a protective factor in colon cancer (OR = 0.770; 95% CI: 0.653 - 0.909; p = 0.002). A decreased risk of colon cancer in patients with rs1800872 AC genotype (OR = 0.794; 95% CI, 0.664 - 950; p = 0.011), CC genotype (OR = 0.589; 95% CI, 0.372 - 0.933; p = 0.022) or AC/CC genotype (OR = 792; 95% CI, 0.678 - 0.925; p = 0.003) was observed, compared with the common AA genotype. Conversely, carriers of the variant T allele of rs3024505 flanking the IL-10 gene were at increased risk of IBD (OR = 1.999; 95% CI: 1.174 - 3.401; p = 0.009). Compared with the common CC genotype, carrying heterozygous (OR = 1.762; 95% CI, 1.030 - 3.012; p = 0.036), or heterozygous and homozygous combined (OR = 1.874; 95% CI, 1.105 - 3.177; p = 0.018) at the IL-10 rs3024505, was associated with increased risk of IBD. Stratified analysis showed that a positive association was identified between the AC/CC genotype at IL-10 rs1800872 and tumor stage (p = 0.029). Conclusions: These data suggest that the variants in the IL-10 gene may change the risk of both colon cancer and IBD. The C allele at rs1800872 may be a protective factor in colon cancer and the T allele at rs3024505 may be a risk factor in IBD in a Han Chinese population.
引用
收藏
页码:1147 / 1154
页数:8
相关论文
共 50 条
  • [31] Genetic polymorphisms present in IL10, IL23R, NOD2, and ATG16L1 associated with susceptibility to inflammatory bowel disease in Mexican population
    Quiroz-Cruz, Sarai
    Posada-Reyes, Berenice
    Alatorre-Garcia, Thalia
    Manuel Del Real-Calzada, Carlos
    Garcia-Samper, Xochitl
    Escobar-Gutierrez, Alejandro
    Arturo Vazquez-Chacon, Carlos
    Armando Martinez-Guarneros, Jose
    Cruz-Rivera, Mayra
    Vaughan, Gilberto
    Fonseca-Coronado, Salvador
    EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2020, 32 (01) : 10 - 16
  • [32] Association of IL-10 polymorphisms with prostate cancer risk and grade of disease
    Jessica M. Faupel-Badger
    La Creis Renee Kidd
    Demetrius Albanes
    Jarmo Virtamo
    Karen Woodson
    Joseph A. Tangrea
    Cancer Causes & Control, 2008, 19 : 119 - 124
  • [33] Association of IL-10 polymorphisms with prostate cancer risk and grade of disease
    Faupel-Badger, Jessica M.
    Kidd, La Creisi Renee
    Albanes, Demetrius
    Virtamo, Jarmo
    Woodson, Karen
    Tangrea, Joseph A.
    CANCER CAUSES & CONTROL, 2008, 19 (02) : 119 - 124
  • [34] TGF-β1 and IL-10 single nucleotide polymorphisms as risk factors for oral cancer in Taiwanese
    Hsu, Han-Jen
    Yang, Yi-Hsin
    Shieh, Tien-Yu
    Chen, Chung-Ho
    Kao, Yu-Hsun
    Yang, Chia-Fu
    Ko, Edward Cheng-Chuan
    KAOHSIUNG JOURNAL OF MEDICAL SCIENCES, 2015, 31 (03) : 123 - 129
  • [35] Genetic variants of IL-10 promoter influence susceptibility to HIV-1 infection and disease progression in the Polish population IL-10 polymorphisms and HIV-1
    Bratosiewicz-Wasik, Jolanta
    Wasik, Tomasz J.
    HUMAN IMMUNOLOGY, 2024, 85 (05)
  • [36] Association of IL-23R and IL-10 variations with Behçet disease: a genetic analysis study
    Yenmis, Guven
    Sabancelebi, Sema
    Atak, Evren
    Yalinkilic, Sila Basak
    Soydas, Tugba
    Sadikoglu, Tumay
    IMMUNOLOGIC RESEARCH, 2024, 72 (02) : 293 - 298
  • [37] Genetic polymorphisms in IL-7 and IL-7R are correlated with lung cancer risk in the Chinese Han population
    Zhang, Chan
    Su, Pincan
    Chen, Wanlu
    Li, Qi
    Dai, Run
    Cheng, YuJing
    Yang, Jiangcun
    CANCER MANAGEMENT AND RESEARCH, 2019, 11 : 5393 - 5401
  • [38] Association between IL-10 rs3024505 and susceptibility to inflammatory bowel disease: A systematic review and meta-analysis
    Liu, Meiling
    Yuan, Wang
    Park, Sunmin
    CYTOKINE, 2022, 149
  • [39] Evidence for non-neutralizing autoantibodies against IL-10 signalling components in patients with inflammatory bowel disease
    Frede, Natalie
    Glocker, Erik-Oliver
    Wanders, Jennifer
    Engelhardt, Karin R.
    Kreisel, Wolfgang
    Ruemmele, Frank M.
    Grimbacher, Bodo
    BMC IMMUNOLOGY, 2014, 15
  • [40] Genetic predisposition of IL-10 promoter polymorphisms with risk of multiple sclerosis: A meta-analysis
    Ramakrishnan, V.
    Husain, R. S. Akram
    Ahmed, Shiek S. S. J.
    JOURNAL OF NEUROIMMUNOLOGY, 2017, 306 : 11 - 18